Get to know our clinical trials
Ensayo clínico de GEN3014 (HexaBody®-CD38) en el mieloma múltiple resistente al tratamiento o recidivante y otras neoplasias malignas hematológicas
LA FINALIDAD DE ESTE ENSAYO ES INVESTIGAR LA SEGURIDAD QUE OFRECE EN PACIENTES CON DISTINTOS TIPOS DE CÁNCERES DE LA SANGRE Y ENCONTRAR LA MEJOR DOSIS PARA TRATAR SU ENFERMEDAD.
Status
In recruitment
Technical Summary
- ENSAYO DE FASE I/II, MULTICÉNTRICO, SIN ENMASCARAMIENTO DE GEN3014 (HEXABODY®-CD38) EN EL MIELOMA MÚLTIPLE RESISTENTE AL TRATAMIENTO O RECIDIVANTE Y OTRAS NEOPLASIAS MALIGNAS HEMATOLÓGICAS
- Code EudraCT: 2020-003781-40
- Protocol number: GCT3014-01
- Promoter: Genmab A/S
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.